Pancreatic adenocarcinoma metastatic
Information
- Disease name
- Pancreatic adenocarcinoma metastatic
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01053013 | Completed | Phase 2 | Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer | April 15, 2010 | April 16, 2016 |
| NCT02179970 | Completed | Phase 1 | To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers | June 2015 | December 14, 2018 |
| NCT02195180 | Completed | Phase 2 | Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma | July 2014 | November 2017 |
| NCT01715142 | Completed | Early Phase 1 | Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer | March 21, 2013 | April 30, 2017 |
| NCT06006728 | Completed | Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy | October 6, 2023 | October 31, 2023 | |
| NCT03529175 | Completed | Phase 2 | Scheduling Nab-paclitaxel With Gemcitabine | January 2014 | June 2016 |
| NCT06076837 | Not yet recruiting | Phase 1 | The Seven Trial: Exploiting the Unfolded Protein Response | December 2023 | December 2025 |
| NCT06396637 | Recruiting | Phase 2 | PD-1 Antibody and Sapropterin Dihydrochloride in Patients With PDAC | April 30, 2024 | April 30, 2025 |
| NCT03633734 | Recruiting | Phase 1/Phase 2 | Efficacy Evaluation of Sequential Treatment With AG and Modified Folfirinox in Metastatic Pancreatic Adenocarcinoma | July 1, 2018 | December 31, 2024 |
| NCT04150042 | Recruiting | Phase 1 | SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells | January 13, 2021 | December 2025 |
| NCT05077800 | Recruiting | Phase 2 | FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer | March 21, 2022 | July 31, 2026 |
| NCT05360264 | Recruiting | Phase 2 | tailOred dRug repurposIng of dEcitabine in KRAS-dependeNt refracTory pAncreaTic cancEr | January 15, 2022 | February 2025 |
| NCT06051851 | Recruiting | Phase 2 | Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer | July 1, 2023 | July 1, 2026 |
| NCT03213626 | Terminated | Phase 2 | Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma | October 13, 2017 | November 18, 2019 |
| NCT03127124 | Withdrawn | Phase 1/Phase 2 | QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer | February 27, 2018 | December 6, 2023 |